TTM
$10.39B
YoY change
+45.8%
5Y CAGR
+26.3%
Peak year (2025)
$10.26B
Cumulative net income
$127.62B
Net Income history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $10.26B
Net Income growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +45.8%
Net Income history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $10.26B | +45.8% | +$3.22B | ||
| 2024 | $7.04B | +18.1% | +$1.08B | ||
| 2023 | $5.96B | +81.1% | +$2.67B | ||
| 2022 | $3.29B | +2835.7% | +$3.18B | ||
| 2021 | $112.00M | -96.5% | −$3.08B | ||
| 2020 | $3.20B | +139.4% | +$1.86B | ||
| 2019 | $1.33B | -38.1% | −$820.00M | ||
| 2018 | $2.15B | -28.2% | −$846.00M | ||
| 2017 | $3.00B | -14.2% | −$498.00M | ||
| 2016 | $3.50B | +23.9% | +$674.00M | ||
| 2015 | $2.83B | +129.1% | +$1.59B | ||
| 2014 | $1.23B | -51.8% | −$1.32B | ||
| 2013 | $2.56B | -59.0% | −$3.68B | ||
| 2012 | $6.24B | -37.1% | −$3.68B | ||
| 2011 | $9.92B | +23.1% | +$1.86B | ||
| 2010 | $8.05B | +7.1% | +$532.00M | ||
| 2009 | $7.52B | +23.3% | +$1.42B | ||
| 2008 | $6.10B | +9.0% | +$506.00M | ||
| 2007 | $5.59B | -7.4% | −$448.00M | ||
| 2006 | $6.04B | +28.4% | +$1.34B | ||
| 2005 | $4.71B | +28.4% | +$1.04B | ||
| 2004 | $3.66B | +20.7% | +$628.00M | ||
| 2003 | $3.04B | +7.0% | +$198.60M | ||
| 2002 | $2.84B | -31.7% | −$1.32B | ||
| 2001 | $4.16B | +63.6% | +$1.62B | ||
| 2000 | $2.54B | +122.4% | +$1.40B | ||
| 1999 | $1.14B | -3.6% | −$42.72M | ||
| 1998 | $1.19B | -1.8% | −$21.61M | ||
| 1997 | $1.21B | +9.6% | +$105.63M | ||
| 1996 | $1.10B | +112.1% | +$581.95M | ||
| 1995 | $519.19M | -25.0% | −$173.40M | ||
| 1994 | $692.59M | +8.6% | +$55.05M | ||
| 1993 | $637.54M | +425.4% | +$516.20M | ||
| 1992 | $121.34M | -81.2% | −$524.22M | ||
| 1991 | $645.56M | +50.8% | +$217.34M | ||
| 1990 | $428.22M | — | — |
- 2025$10.26B+45.8%
- 2024$7.04B+18.1%
- 2023$5.96B+81.1%
- 2022$3.29B+2835.7%
- 2021$112.00M-96.5%
- 2020$3.20B+139.4%
- 2019$1.33B-38.1%
- 2018$2.15B-28.2%
- 2017$3.00B-14.2%
- 2016$3.50B+23.9%
- 2015$2.83B+129.1%
- 2014$1.23B-51.8%
- 2013$2.56B-59.0%
- 2012$6.24B-37.1%
- 2011$9.92B+23.1%
- 2010$8.05B+7.1%
- 2009$7.52B+23.3%
- 2008$6.10B+9.0%
- 2007$5.59B-7.4%
- 2006$6.04B+28.4%
- 2005$4.71B+28.4%
- 2004$3.66B+20.7%
- 2003$3.04B+7.0%
- 2002$2.84B-31.7%
- 2001$4.16B+63.6%
- 2000$2.54B+122.4%
- 1999$1.14B-3.6%
- 1998$1.19B-1.8%
- 1997$1.21B+9.6%
- 1996$1.10B+112.1%
- 1995$519.19M-25.0%
- 1994$692.59M+8.6%
- 1993$637.54M+425.4%
- 1992$121.34M-81.2%
- 1991$645.56M+50.8%
- 1990$428.22M—
Net Income values are taken from AstraZeneca's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current net income (TTM) is $10.39B. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
AstraZeneca (AZN) most recent annual net income stands at $10.26B (2025) – surged 45.8% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca net income compounded at +26.3% per year, sustaining 4 straight years of year-over-year growth.
The record annual net income stands at $10.26B, reached in 2025; the historical low of $112.00M was recorded in 2021.
AstraZeneca Net Income by Year
AstraZeneca Net Income 2025: $10.26B
2025's net income for AstraZeneca came in at $10.26B, surged 45.8% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca Net Income 2024: $7.04B
AstraZeneca posted net income of $7.04B in 2024, grew 18.1% from 2023.
AstraZeneca Net Income 2023: $5.96B
In 2023, AstraZeneca reported net income of $5.96B, surged 81.1% from 2022.
AstraZeneca Net Income 2022: $3.29B
AstraZeneca net income in 2022 was $3.29B, surged 2835.7% from 2021.
AstraZeneca Net Income 2021: $112.00M
AstraZeneca net income in 2021 was $112.00M.
See more financial history for AstraZeneca (AZN).
Sector peers by Net Income
Healthcare peers of AstraZeneca (AZN), ranked by their latest net income
| $26.80B | |
| $20.64B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $7.71B | |
| $6.74B | |
| $4.23B |
- $26.80B
- $20.64B
- $18.25B
- $15.97B
- $12.06B
- $7.71B
- $4.23B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation